Skip to main
DRTS
DRTS logo

DRTS Stock Forecast & Price Target

DRTS Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Tau Medical Ltd has achieved a significant operational milestone by securing a radioactive material license in New Hampshire, enabling the company to start U.S. manufacturing of its proprietary Alpha DaRT technology, set to begin in 2026. The company maintains a strong cash position, which supports its ongoing development and manufacturing efforts in the lucrative oncology market. Although Alpha Tau reported a net loss of $11.7 million, which was slightly higher than previous estimates, the potential of Alpha DaRT to meet unmet needs in oncology remains a key driver for investor interest and future growth.

Bears say

Alpha Tau Medical reported a net loss of $11.7 million in the third quarter of 2025, highlighting its ongoing financial struggles as a clinical-stage oncology company. The outlook for the company's proprietary Alpha DaRT technology is clouded by significant risks, including potential failures in clinical trials, challenges in obtaining regulatory approval in the U.S., and difficulties in achieving commercial success due to market limitations and competition. Additionally, the presence of potential dilution risks may further undermine investor confidence and the overall financial stability of Alpha Tau Medical.

DRTS has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Tau Medical (DRTS) Forecast

Analysts have given DRTS a Strong Buy based on their latest research and market trends.

According to 2 analysts, DRTS has a Strong Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Tau Medical (DRTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.